Three Consecutive Years of Recognition
On March 25, the "Shenzhen Medical Aesthetics Capital High-Quality Development Forum and the 3rd General Election of the Shenzhen Plastic and Cosmetic Surgery Industry Association" was successfully held in Luohu, Shenzhen.
Themed "Shenzhen's Beauty Power — Quality as Beauty," the conference attracted nearly 500 participants including government leaders, corporate representatives, academic experts, and industry leaders. Through in-depth policy interpretation, compliance governance discussions, cutting-edge trend analysis, and benchmark case sharing, the event built consensus and explored pathways to advance the construction of Shenzhen as the "Medical Aesthetics Capital," injecting new momentum into the industry's high-quality development.
At the conference, Medgen Life Science once again received the "Quality, Safe, and Trusted Medical Aesthetics Service Provider" award from the Shenzhen Plastic and Cosmetic Surgery Industry Association. This marks the third consecutive year that Medgen Life Science has received this honor — a strong affirmation of the company's past achievements and full recognition of the team's pursuit of excellence.
Product Portfolio
Medgen Life Science is a high-tech biomedical enterprise focused on the integrated R&D and manufacturing of novel regenerative repair materials in biomaterials, regenerative engineering, and translational medicine.
The company has successfully launched China's first pre-filled injectable artificial bone (BoneSwift™), which offers convenient operation and significantly reduces surgical time. Medgen has also developed a platelet-rich plasma (PRP) preparation device featuring a unique three-chamber independent sealed design and a secondary gradient centrifugation method, ensuring efficiency and safety in the preparation process and contributing important technological innovation to the medical aesthetics field.
Additionally, the company's independently developed oral bone repair material (PoroGraft®) registration application has been accepted by the National Medical Products Administration and is expected to receive market approval soon, marking another solid step forward in Medgen's product R&D and innovation.
Balanced Development
Since its founding, Medgen Life Science has been committed to achieving balanced development across both clinical medicine and consumer healthcare, building a multi-field, multi-product natural-material regenerative repair platform. Through continuous technological innovation and product diversification, the company provides patients with superior treatment solutions, advances the regenerative repair materials industry, and makes positive contributions to the medical aesthetics sector as a whole.
Looking ahead, Medgen Life Science will continue to uphold its founding mission, continuously improve service quality, and provide clients with trusted, high-quality medical aesthetics services, striving to become a leader and benchmark in the industry and contributing to its high-quality development.